Goodpasture Syndrome Clinical Trials and Treatments

Goodpasture syndrome (GPS) is a rare autoimmune pulmonary-renal vasculitis characterized by autoantibodies against the alpha-3 chain of type IV collagen in basement membranes. Pathophysiology involves IgG autoantibodies depositing along the glomerular basement membrane and pulmonary alveolar basement membrane, activating complement and recruiting neutrophils causing tissue destruction. The pathologic hallmark is linear IgG deposition along basement membranes.

The most common symptoms of Goodpasture Syndrome include Hemoptysis and pulmonary hemorrhage, Dyspnea and respiratory failure, Hematuria and proteinuria, Progressive renal dysfunction, Anemia and fatigue, among others. Goodpasture Syndrome affects approximately 1 in 1,000,000 people; accounts for 1-2% of pulmonary hemorrhage cases. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Goodpasture Syndrome from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Plasma exchange combined with corticosteroids (methylprednisolone induction followed by oral prednisone) and cyclophosphamide is the standard emergency therapy, removing circulating anti-GBM antibodies while suppressing further antibody production. Treatment must be initiated urgently (ideally within days of symptom onset) as kidney outcomes worsen significantly with delay.

As of September 2026, Trial Friend's curated drug index does not include an FDA-approved treatment specific to Goodpasture Syndrome. The Treatments section of this page checks FDA drug labels live and lists any approved drug whose label names the condition, and the trials listed below cover the investigational options.

The exact cause of Goodpasture Syndrome is not fully understood. It is not caused by a single gene; inherited variants raise risk, and immune, environmental or other triggers are thought to set it off. Autoimmune anti-GBM disease with HLA association; diagnosis rests on anti-GBM antibodies and biopsy, not genetic testing. The condition affects approximately 1 in 1,000,000 people; accounts for 1-2% of pulmonary hemorrhage cases. Research is ongoing to better understand the disease mechanism.

No single gene test diagnoses Goodpasture Syndrome. The diagnosis rests on clinical findings and laboratory or imaging results; genetic variants shift risk rather than cause the disease. Autoimmune anti-GBM disease with HLA association; diagnosis rests on anti-GBM antibodies and biopsy, not genetic testing.

Some trials collect genetic samples for research or check specific risk markers. The Genetic Testing section of this page shows any tests listed in the NIH Genetic Testing Registry, which for this condition are usually research or risk-marker tests rather than diagnostic ones.

Eligibility for Goodpasture Syndrome clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Goodpasture Syndrome clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.